26.06.2012 • News

Siegfried Appoints René Imwinkelried Head of R&D

The Board of Directors of Siegfried Holding appointed René Imwinkelried, Ph.D., the company's new Head Research & Development and member of the Executive Committee. He is currently Head of Technical Development Small Molecules at Roche in Basel. René Imwinkelried will start in his new function on September 1st, 2012.

He succeeds Wolfgang Wienand, Ph.D., who held this position since August 2010 and will now focus on further developing Strategy and Mergers & Acquisitions in the Executive Committee and on his responsibility for Legal and IP Management. Wolfgang Wienand will continue to execute both functions until René Imwinkelried joins Siegfried.

For personal reasons, Beat In-Albon, Ph.D., has with immediate effect resigned from the Board of Directors of Siegfried Holding.

 

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.